Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
T. Maher (London, United Kingdom), J. Simpson (Stevenage, United Kingdom), J. Porter (London, United Kingdom), R. Chan (Stevenage, United Kingdom), R. Eames (Stevenage, United Kingdom), Y. Cui (Stevenage, United Kingdom), S. Siederer (Stevenage, United Kingdom), S. Parry (Stevenage, United Kingdom), J. Kenny (Stevenage, United Kingdom), R. Slack (London, United Kingdom), R. Marshall (London, United Kingdom), J. Sahota (London, United Kingdom), G. Rizzo (London, United Kingdom), G. Searle (London, United Kingdom), F. Wilson (Stevenage, United Kingdom), A. Saleem (London, United Kingdom), A. Kang'Ombe (Stevenage, United Kingdom), D. Fairman (Stevenage, United Kingdom), W. Fahy (Stevenage, United Kingdom), M. Vahdati-Bolouri (Stevenage, United Kingdom). Late Breaking Abstract - A PET imaging study to confirm target engagement in the lungs of patients with IPF following a single dose of a novel inhaled avß6 integrin inhibitor. 246

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - PK/PD assessment of an oral, selective aVß6/aVß1 integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Late Breaking Abstract - Multiple ascending dose study of the inhaled IL-4Ra antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Late Breaking Abstract - Evidence of target engagement and pathway modulation: biomarker analysis of the phase 1b inhaled seralutinib study Source: Virtual Congress 2021 – Pathogenesis and pathophysiology of pulmonary hypertension Year: 2021 Late Breaking Abstract - Preclinical study of anti-interleukin-4 alpha single domain antibody with therapeutic potential in asthma by oral inhalation Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Late Breaking Abstract - A novel bronchoscopic lung volume reduction device for severe emphysema: a preclinical study in pigs Source: International Congress 2018 – Interventional pulmonology highlights in 2018: latest innovations Year: 2018 Absence of early metabolic response assessed by 18F-FDG PET-CT after initiation of antifibrotic drugs in IPF patients. Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018 A novel lung pharmacokinetic model predicts lung exposure and supports dose selection for clinical study of AZD2115, a dual muscarinic receptor antagonist/beta2 adrenoceptor agonist (MABA) Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD Year: 2015 Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis) Source: International Congress 2018 – Integrated care and non-pharmacological management of COPD Year: 2018 Using a selective avß6 PET ligand to optimise early phase IPF clinical trials Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 Late Breaking Abstract - Phase 1 dose escalation study of aerosolized pirfenidone in normal healthy volunteers (NHV), smokers, and IPF patients Source: International Congress 2018 – ILDs: From bench to bedside Year: 2018 Late Breaking Abstract - Comparative real world effectiveness of triple therapy versus dual bronchodilation in frequently exacerbating patients with COPD Source: International Congress 2018 – COPD exacerbations and bronchiectasis Year: 2018 Late Breaking Abstract - Tiotropium/olodaterol improves pulmonary function in patients with treatment naive COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Late Breaking Abstract - Phase 2 trial evaluating the effects of dexpramipexole on blood eosinophils, lung function, and airway biomarkers in eosinophilic asthma Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Combined assessment of regional lung function and morphology using a contrast enhanced Dual-Energy CT protocol: Prospective value of functional imaging biomarkers in longitudinal analysis of patients with Interstitial Lung Disease Source: Virtual Congress 2020 – What is new in interstitial lung diseases of known origin? Year: 2020 Changes in pulmonary 18F-FDG SUVmax reflect treatment response in patients with diffuse parenchymal lung disease; a PET/CT proof of concept study Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease Year: 2010 An inhaled “bifunctional” dual PDE3/4 inhibitor provides additional short-term improvements in lung function compared to existing classes of bronchodilator: implications for future treatment of COPD Source: Eur Respir J, 52 (5) 1801675; 10.1183/13993003.01675-2018 Year: 2018 Late Breaking Abstract - ND-L02-s0201 treatment leads to efficacy in preclinical IPF models Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Effect of low dose pirfenidone on survival and lung function decline in patients with idiopathic pulmonary fibrosis (IPF): results from a real life study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Late Breaking Abstract - Spatial pharmacokinetics of inhaled drugs in human lung – evaluation of regional lung targeting by direct sampling of epithelial lining fluid Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Modelling and simulation in successful drug development programmes: Characterisation of exacerbation reduction with roflumilast to corroborate the importance of defining patient subsets in COPD Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011